Coronary Flow Reserve Changes After Semaglutide Treatment

NCT07190144 · Completed

Last updated 2026-05-28

This trial tested how semaglutide affects blood flow in the heart arteries of adults with diabetes, obesity, or overweight who have had a heart-related event.

Status Completed The study has finished.

Type Observational

Participants 122 people

Who can join Ages 28–65 · all sexes

Timeline Started 2025-01 · est. completion 2025-08

Where 1 site · Turkey (Türkiye)

What this study is testing ClinicalTrials.gov NCT07190144 ↗

Description as written by the study sponsor.

The goal of this observational study is to learn about the effects of semaglutide to coronary artery flow in diabetic and non-diabetic patients. The main question it aims to answer is: Does semaglutide enhance coronary artery flow in diabetic and non-diabetic patients? Participants already planned taking semaglutide by an endocrine specialist as their treatment was assessed with CFR before and 3 months after.

Main thing measured	Number of patients who had acute coronary syndrome
Sponsor	Ekrem Bilal Karaayvaz
Conditions studied	The Study Focused on the Vascular Effects of Semaglutide in Both Diabetic and Non-diabetic Patients, Obesity &Amp; Overweight
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07190144 ↗